Morningstar

Revvity Inc RVTY

Morningstar Rating
Unlock
Stock XNYS Rating as of
$126.06 −0.28 (0.22%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Revvity Waiting for Demand to Fully Recover, as Macro Headwinds Still Pressure Business

Julie Utterback, Ava Gams

With myriad acquisitions in the past few years, Revvity (formerly PerkinElmer) has been in a constant state of evolution since 2016 when the company made the transition into two new business segments, diagnostics and discovery and analytical solutions, or DAS. With the recent divestment of its Applied, Food, and Enterprise Services business in early 2023, the company is operating under a new name and will focus solely on the life sciences and diagnostics business. We believe the firm's renewed strategic focus on improving its diagnostic product mix and life sciences business will maintain returns over cost of capital and produce tangible benefits for shareholders in the long run.

Read Full Report

Price vs Fair Value

View History
RVTY is trading at a 335% premium.
Price
$126.06
Fair Value
$536.00
Uncertainty
Medium
1-Star Price
$233.10
5-Star Price
$193.30
Economic Moat
Hkfdwrv
Capital Allocation
Rblfhclw

Bulls Say, Bears Say

Bulls

Revvity possesses a well-entrenched niche in newborn screening and stands to benefit from growing menu expansion globally and expanding to emerging markets, particularly China and India.

Bears

Declining birthrates and overpopulation in China and India could slow Revvity's growth in diagnostics, particularly in newborn screening.

Show More

News

View All

Trading Information

Previous Close Price
$126.34
Day Range
$125.49–127.91
52-Week Range
$79.50–128.15
Bid/Ask
$50.43 / $200.43
Market Cap
$15.55 Bil
Volume/Avg
680,453 / 777,178

Key Statistics

Price/Earnings (Normalized)
27.23
Price/Sales
5.75
Dividend Yield (Trailing)
0.22%
Dividend Yield (Forward)
0.22%
Total Yield
1.16%

Company Profile

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
11,500
Website
https://www.revvity.com

Competitors

Valuation

View More
Metric
RVTY
A
WAT
Price/Earnings (Normalized)
 27.2328.4731.62
Price/Book Value
 1.987.2115.02
Price/Sales
 5.756.697.40
Price/Cash Flow
 22.9423.8725.59
Price/Earnings
RVTY
A
WAT

Financial Strength

Metric
RVTY
A
WAT
Quick Ratio
 1.841.261.23
Current Ratio
 2.271.782.10
Interest Coverage
 2.2218.066.96
Quick Ratio
RVTY
A
WAT

Profitability

Metric
RVTY
A
WAT
Return on Assets (Normalized)
 1.93%14.06%14.83%
Return on Equity (Normalized)
 3.35%25.67%61.05%
Return on Invested Capital (Normalized)
 2.33%17.76%21.55%
Return on Assets
RVTY
A
WAT

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
LzsgckhftwRzhks$234.7 Bil
 Danaher Corp
DHR
YfynvgjfcwYqtsthy$198.9 Bil
 IQVIA Holdings Inc
IQV
VfhxlrvgMyhnfk$42.8 Bil
 Agilent Technologies Inc
A
XjmscnphrzVknxt$42.5 Bil
 IDEXX Laboratories Inc
IDXX
BjypkgwfdmTgwjd$42.1 Bil
 Mettler-Toledo International Inc
MTD
SxnplhnjtvKcnnt$31.4 Bil
 Icon PLC
ICLR
NpvplprLymhfvd$23.7 Bil
 Waters Corp
WAT
HrdjfxmqdnPpcy$21.2 Bil
 Illumina Inc
ILMN
DnrgjrbgcSrvjnv$20.7 Bil
 Labcorp Holdings Inc
LH
YdbbvnlsGgkkxv$18.6 Bil

Sponsor Center